Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

Official title

Investigating Precision Medicine in the Adjuvant Setting: a Phase 3 Clinical Trial in Biliary Tract Cancer

Overview

The objective of SAFIR-IMPACT BTC is to see whether, combining or replacing the standard adjuvant chemotherapy with a targeted therapy matched to the person's cancer, is better than the standard treatment alone in delaying or preventing the return of the cancer. Three different targeted therapies will be evaluated, each of which recognises a different type of abnormality in cancer cells: * Ivosidenib - a drug which acts on a specific abnormality in a protein called IDH1. * Futibatinib - a drug which acts on abnormalities in a protein called FGFR2 * Zanidatamab - a drug which acts on cancers that produce more than the usual quantity of a protein called HER2. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a sample of the patient's tumour will be tested to see if it has one of the target abnormalities being studied (ii) a randomised comparative phase (for selected patients only) which consists of comparing two treatment options: some patients will receive the targeted therapy specific to the abnormality identified in their tumour, while others will receive the standard treatment. Patients will be assigned to one treatment or the other by a random draw: they will have a 2 in 3 chance of receiving the targeted therapy. Randomised participants will: * Take their assigned treatment for 6 months * Visit the clinic once every 3 weeks for checkups and tests * Keep a diary of their symptoms and the treatment they take at home Follow-up information will be collected for all participants until the end of the trial.

Detailed description

This is a multicentre, randomised phase 3, open-label trial to evaluate whether a precision oncology strategy of adjuvant molecular targeted therapy (MTT) can decrease the risk of relapse in the treatment of patients with resected biliary tract cancer (BTC) whose tumour harbours target (ESCAT I) alterations. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial. The aim of the screening phase is to identify a medically suitable population, to obtain a molecular profile of the patient's tumour, to collect baseline data concerning patient demographics and disease characteristics and to obtain pre-treatment tumour samples for further translational research. A genetic profile will be obtained from tumour-derived DNA and RNA samples by next-generation sequencing. The trial Molecular Tumour Board will determine whether each patient harbours a targetable molecular alteration for one or more of the trial MTTs. Patients who have sufficiently recovered from surgery, with no measurable disease on post-operative imaging (in the opinion of the investigator), and whose tumour harbours at least one targetable molecular alteration, will be invited to participate in the randomised phase of the trial in which 280 eligible patients will be randomised (2:1) to receive adjuvant therapy with either a matched MTT (combined with SoC or alone depending on the alteration) or to continue 1L-SoC treatment.

Interventions

• Drug Futibatinib
  Dose 20 mg once a day (QD)
• Drug Ivosidenib + Capecitabine
  Ivosidenib: Dose 500 mg QD Capecitabine: 1250mg/m² BID for 14 days on, 7 days off, in 3 week cycles
• Drug Zanidatamab + Capecitabine
  Zanidatamab: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W Capecitabine: 1250mg/m² BID for 14 days on, 7 days off, in 3 week cycles
• Drug Capecitabine (Xeloda)
  1250mg/m² BID for 14 days on, 7 days off, in 3 week cycles

Primary outcome measures

• Relapse-free survival [Time frame: From randomisation to disease or death, up to 5 years]

Secondary outcome measures (8)

• Overall Survival [Time frame: From randomisation to death, up to 5 years]
• Post-relapse survival [Time frame: From randomisation to death, up to 5 years]
• ctDNA-clearance [Time frame: From randomisation to 24 weeks]
• Time-to-ctDNA recurrence [Time frame: From randomisation, up to 5 years]
• Incidence of Adverse Events [Time frame: From randomisation, up to 5 years]
• Quality of life questionnaire - Core 30 (QLQ-C30) [Time frame: At Baseline, after 42 days (at Cycle 3), after 105 days (at Cycle 6) and after 168 days (end of treatment)]
• Quality of life Questionnaire - Biliary tract cancer module (QLQ-BIL21) [Time frame: At Baseline, after 42 days (at Cycle 3), after 105 days (at Cycle 6) and after 168 days (end of treatment)]
• EuroQOL EQ-5D-5L questionnaire [Time frame: At Baseline, after 42 days (at Cycle 3), after 105 days (at Cycle 6) and after 168 days (end of treatment)]

Eligibility criteria

SCREENING PHASE

Inclusion criteria

• Signed a written informed consent form prior to any trial specific procedures (Consent #1)
• Histologically-proven intrahepatic cholangiocarcinoma, perihilar or distal extrahepatic cholangiocarcinoma or gallbladder carcinoma (ampullary carcinoma is excluded)
• Macroscopically complete resection of the primary tumour (R0 or R1 surgical margin status)
• Aged ≥18 years
• Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).

Exclusion criteria

• Contraindication to standard adjuvant therapy
• Prior anticancer therapy in the neoadjuvant or adjuvant setting.
• Patients with gallbladder cancer which has not extended to involve the muscle layers or lymph nodes (pT1aN0)
• Planned post-operative radiation therapy
• Prior treatment with any of the MTT under investigation in the trial
• Other invasive malignancies, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 3 years or more and are deemed at negligible risk for recurrence, are eligible for the trial
• Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
• Women who are pregnant or breast-feeding
• Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
• Individuals deprived of liberty or placed under protective custody or guardianship

RANDOMISED PHASE Inclusion criteria

• Signed a written informed consent form prior to any trial specific procedures (Consent #2)
• Molecular profile showing the tumour harbours at least one targetable molecular alteration with a MTT in the study portfolio (as determined by the trial MTB)
• Surgery performed at least four weeks prior to randomisation with adequate wound healing (in the Investigator's opinion) to allow adjuvant therapy to be initiated
• No measurable disease, as assessed by the investigator: normal post-operative thoracic, abdominal and pelvic CT scan or normal MRI of abdomen and pelvis + normal chest CT performed within 4 weeks prior to randomisation
• ECOG performance status of 0 or 1
• Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and haemoglobin ≥9 g/dL
• Adequate liver function: total bilirubin level ≤1.5 × the upper limit of normal (ULN) range (total bilirubin ≤3.0 ULN when the patient has documented Gilbert syndrome), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN
• Adequate renal function: estimated creatinine clearance ≥50 mL/min according to the Cockcroft-Gault formula, or estimated glomerular filtration rate (eGFR) value ≥50 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
• Men, and women of childbearing potential (WOCBP) must agree to use adequate contraception for the duration of trial participation and as required after completing study treatment. Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period.

Note: See Section 5.8.5 for a definition of adequate contraception and required duration of contraceptive use following treatment with individual MTTs.

• Women of childbearing potential must have a negative serum pregnancy test performed within 3 days before the date of randomisation
• Willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests, and other study procedures
• Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).

Exclusion criteria

• Disease relapse occurring at any time prior to randomisation
• Surgery performed more than 16 weeks prior to randomisation
• Previous adjuvant treatment, including any systemic treatment, or radiotherapy
• Inability or unwillingness to swallow pills
• History of malabsorption syndrome or other condition that would interfere with enteral absorption. For example, active intestine inflammation (e.g., Crohn's disease or ulcerative colitis) requiring immunosuppressive therapy
• Contraindication or known hypersensitivity to capecitabine or fluorouracil or to the MTT for the molecular alteration found in the patient, or any component in their formulation Note: For patients with multiple target alterations, contraindication to one MTT will not warrant exclusion if MTT to an alternative target is feasible.
• Radiotherapy within 7 days of randomisation
• History of severe and unexpected reactions to fluoropyrimidine therapy
• Known complete dihydropyrimidine dehydrogenase (DPD) deficiency
• Recent or concomitant treatment with brivudine
• History of myocardial infarction or unstable angina within 6 months prior to enrolment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure.
• Patients with a heart-rate corrected QT interval (using Fridericia's formula) (QTcF) ≥ 450 msec or other factors that increased the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalaemia, family history of long QT interval syndrome).
• Patients with HBV with HBV-DNA higher than 500IU/mL, active untreated HCV infection, or HIV infection with CD4 below 200. Patients with controlled HBV, HCV and HIV infections are allowed.
• Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
• Women who are pregnant or breast-feeding
• Participation in another therapeutic trial within the 30 days prior to entering the study (participation in an observational trial would be acceptable)
• Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
• Individuals deprived of liberty or placed under protective custody or guardianship

ADDITIONAL EXCLUSION CRITERIA FOR SPECIFIC MTTs:

Futibatinib cohort

• History and/or current evidence of any of the following disorders:

• Non-tumour related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator. Blood phosphate concentration should be ≤ ULN at baseline examination.
• Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator
• Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator
• Concomitant treatment with strong CYP3A/P-gp inhibitors or strong or moderate CYP3A/P gp inducers where these cannot be substituted for another therapy.

Ivosidenib cohort

• Patients with history of torsade de pointes
• Concomitant treatment with digoxin where this cannot be substituted for another therapy
• Concomitant treatment with strong CYP3A4 inducers or dabigatran where these cannot be substituted for another therapy
• Concomitant treatment with medicinal products known to prolong the QTc interval, or moderate or strong CYP3A4 inhibitors where these cannot be substituted for another therapy
• Familial history of sudden death or polymorphic ventricular arrhythmia
• Hypokalaemia, hypomagnesemia or hypocalcaemia where this cannot be corrected by supplementation

Zanidatamab cohort

• Total lifetime anthracycline load exceeding 360 mg/m2 Adriamycin® or equivalent.
• Use of corticosteroids administered at doses equivalent to >15 mg per day of prednisone within 2 weeks of first zanidatamab dosing unless otherwise approved by the coordinating investigator. Topical, ocular, intra-articular, intranasal, and/or inhalational corticosteroids are permitted.
• Acute or chronic uncontrolled pancreatitis or Child-Pugh Class B or C liver disease.
• A history of life-threatening hypersensitivity to monoclonal antibodies or recombinant proteins

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07745296 · UC-GMP-2601 - PRODIGE 122 · 2025-524960-38-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗